Orladeyo Recommended in EU as 1st Oral Treatment to Prevent HAE Attacks

Orladeyo Recommended in EU as 1st Oral Treatment to Prevent HAE Attacks

288350

Orladeyo Recommended in EU as 1st Oral Treatment to Prevent HAE Attacks

BioCryst Pharmaceuticals’ Orladeyo (berotralstat) has been recommended for approval in the European Union as the first oral therapy for preventing swelling attacks in people with hereditary angioedema (HAE), ages 12 and older. The recommendation was made by the Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency. The committee’s recommendations are generally accepted by the European Commission (EC), which makes the final decision on approvals for all medicines in…

You must be logged in to read/download the full post.